ICGC: International Cancer Genome Consortium
Summary: The International Cancer Genome Consortium (ICGC) has been organized to launch and coordinate a large number of research projects that have the common aim of elucidating comprehensively the genomic changes present in many forms of cancers that contribute to the burden of disease in people throughout the world.
The primary goals of the ICGC are to generate comprehensive catalogues of genomic abnormalities (somatic mutations, abnormal expression of genes, epigenetic modifications) in tumors from 50 different cancer types and/or subtypes which are of clinical and societal importance across the globe and make the data available to the entire research community as rapidly as possible, and with minimal restrictions, to accelerate research into the causes and control of cancer. The ICGC will facilitate communication among the members and provide a forum for coordination with the objective of maximizing efficiency among the scientists working to understand, treat, and prevent these diseases.
* Spain, Member of the ICGC: Chronic Lymphocytic Leukemia - CLL with mutated and unmutated IgVH (the CLL Consortium)
Scientific Coordinator: Elías Campo Hospital Clinic of Barcelona (HCPB), University of Barcelona (UB)
Summary: Chronic Lymphocytic Leukemia (CLL) is one of the most frequent tumors in Western countries. CLL represents 35% of all leukemias with an incidence of 3-7 per 100.000 habitants and reaches 12-15/100.000 in people over 60 years. The disease is heterogeneous; there are patients who have a long clinical evolution with a stable disease whereas others follow a progressive course with a median survival of 5-8 years. This heterogeneity is due to the existence of two major molecular groups, characterized respectively by the presence or absence of somatic mutations in immunoglobulin genes. Different genetic alterations have been identified associated with particular clinical presentations and evolution. There is also evidence of genetic predisposition, but the initiating genetic alterations are largely unknown in both sporadic and inherited cases. Today, there is no curative therapy for CLL.
As a contributing member of the ICGC, the CLL Consortium will generate a comprehensive catalogue of genetic alterations in 500 independent tumors. Normal and tumour samples with highly purified tumor cell content (>95%) and normal samples with <5% tumor cell contamination will be included.
- Clinical Selection and follow-up
- Epidemiological survey
- Sample Collection and characterization
- DNA/RNA Isolation and Sample Storage
- Genomics Analyses
- Complementary studies
- Data Management and storage
Other Enterprises, Universities and/or Institutions that collaborate/participate in the Project: Hospital Clinic of Barcelona (HCPB), University of Barcelona (UB), University of Oviedo (UniOvi), University Institute of Oncology (IUOPA), Catalan Institute of Oncology (ICO), Center for Genomic Regulation (CRG), Center for Cancer Research (CIC-Salamanca), University Hospital, University of Deusto (UD), National Cancer Research Centre (CNIO), University of Santiago de Compostela (USC), Barcelona Supercomputing Centre (BSC), Pompeu Fabra University (UPF), National Genome Analysis Centre (CNAG).